RxDoctor Payments Data

Violeta Gonzalez, PA

Physician Assistant · Martinsburg, WVNPI 1376547620

Payments from drug & device makers

$1,926in general payments, 2019–2025

Across 98 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$333
  • Novo Nordisk$276
  • Abbott$221
  • Merck$157
  • AstraZeneca$140
  • E.r. Squibb & Sons, L.L.C.$119
  • plus $680 from 12 others

What the payments were for

  • Food & beverage$1,926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,926 in reported general payments places this provider in the 85th percentile of 833 physician assistant providers in West Virginia.

See all physician assistant providers in West Virginia

Medicare billing

Part B allowed, 2024
$46,708
Medicare patients
139
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$51,118
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$38,004
EliquisApixaban31$34,712
JardianceEmpagliflozin31$34,452
OzempicSemaglutide35$32,015
JanuviaSitagliptin Phosphate25$25,161
XareltoRivaroxaban18$19,232
Breo ElliptaFluticasone/Vilanterol25$13,613
Rosuvastatin Calcium169$2,001
Losartan Potassium161$1,936
Famotidine82$1,732
Metoprolol Succinate131$1,651
Potassium Chloride58$1,488
Atorvastatin Calcium168$1,388
Montelukast Sodium64$1,340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$98$51,61775 claims
Lilly USA, LLCMounjaro$333$51,11849 claims
PfizerEliquis$108$34,71231 claims
Boehringer IngelheimJardiance$111$34,45231 claims
Novo NordiskOzempic$276$32,01535 claims
MerckJanuvia$157$25,16125 claims
Johnson & JohnsonXarelto$73$19,23218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 833 physician assistant providers in West Virginia.

Other physician assistant in Martinsburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →